SENSEI BIOTHERAPEUTICS INC. - COMMON STOCK

Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

02 Apr 2025 06:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress

28 Mar 2025 06:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

27 Mar 2025 15:05:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference

04 Feb 2025 06:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones

08 Jan 2025 06:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Participate in Citi’s 2024 Global Healthcare Conference

27 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

14 Nov 2024 06:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences

29 Oct 2024 06:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference

04 Sep 2024 15:05:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Present at Upcoming Conferences

04 Sep 2024 06:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

06 Aug 2024 06:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference

30 May 2024 06:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101

23 May 2024 16:10:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

09 May 2024 06:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting

24 Apr 2024 15:05:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference

09 Apr 2024 06:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment

04 Apr 2024 15:05:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium

22 Mar 2024 06:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences

06 Mar 2024 06:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

28 Feb 2024 06:30:00 By Nasdaq GlobeNewswire